Nihon Suido Consultants (261A) · InitiativeRestated
R&D Investment
First written in FY2024. 3 of 4 entries say "Restated". Latest entry: FY2026-H1.
4entries
2years
0from disclosures
How it moved
Same theme, other companies
Continued company-wide R&D activities and resource investmentA theme 202 companies write about · 0 as a headwind · 215 as a tailwind
34 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 186 companies compared. The sentences above are computed from all 186.Comparing 200 of the theme's 217 threads.Full recordFilings, disclosures and news, newest first
- FY2026-H1RestatedAnnual report
「The total R&D expenses incurred by the Group during the interim consolidated accounting period amounted to ¥80 million.」
R&D activities continued, with total R&D expenses of ¥80 million recorded for the interim consolidated accounting period. - FY2025RestatedAnnual report
「We aim to keep R&D expenses at approximately 1% of net sales. R&D expenses for the consolidated fiscal year were ¥195.495 million.」
The benchmark of approximately 1% of net sales was maintained, and R&D expenses for the year were ¥195.495 million. The company also described a framework for soliciting, selecting, monitoring and budgeting R&D themes and managing their results. - FY2025-H1RestatedAnnual report
「The total R&D expenses incurred by the Group during the interim consolidated accounting period amounted to ¥76 million.」
R&D activities continued, with total R&D expenses of ¥76 million recorded for January through June 2025. No change was indicated to the existing benchmark of approximately 1% of net sales. - FY2024First statedAnnual report
「We aim to keep R&D expenses at approximately 1% of net sales.」
Research covers the core business, PPP and digitalization, industrial infrastructure and new fields, with R&D expenses targeted at approximately 1% of net sales.